Drug intelligence / Profile preview

MSM-707

Development stage: Preclinical
Lead developer: MSM Protein Technologies
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral

Overview

MSM-707 is a monoclonal antibody currently in preclinical development by MSM Medical for the treatment of Graft-Versus-Host Disease (GVHD). The therapeutic candidate is designed to target an undisclosed membrane protein or G protein-coupled receptor (GPCR) to modulate the immune response associated with GVHD. As of the latest pipeline updates, the program is in the lead optimization and preclinical testing phase, focusing on establishing efficacy and safety profiles for potential clinical advancement.

Targets

CCR7 (C-C Motif Chemokine Receptor 7)

Beyond the preview

Go deeper on MSM-707.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSM-707.

Explore the full profile